Abstract

Molecular clock REV-ERBα is central to regulating lung injuries, and decreased REV-ERBα abundance mediates sensitivity to pro-fibrotic insults and exacerbates fibrotic progression. In this study, we determine the role of REV-ERBα in fibrogenesis induced by bleomycin and Influenza A virus (IAV). Bleomycin exposure decreases the abundance of REV-ERBα, and mice dosed with bleomycin at night display exacerbated lung fibrogenesis. Rev-erbα agonist (SR9009) treatment prevents bleomycin induced collagen overexpression in mice. Rev-erbα global heterozygous (Rev-erbα Het) mice infected with IAV showed augmented levels of collagens and lysyl oxidases compared with WT-infected mice. Furthermore, Rev-erbα agonist (GSK4112) prevents collagen and lysyl oxidase overexpression induced by TGFβ in human lung fibroblasts, whereas the Rev-erbα antagonist exacerbates it. Overall, these results indicate that loss of REV-ERBα exacerbates the fibrotic responses by promoting collagen and lysyl oxidase expression, whereas Rev-erbα agonist prevents it. This study provides the potential of Rev-erbα agonists in the treatment of pulmonary fibrosis.

The molecular clock REV-ERBα regulates lung injury during fibrosis, but the role of REV-ERBα in fibrogenesis remains unknown. Here, the authors show that REV-ERBα interacts with the lysyl oxidase-collagen axis during fibrogenesis and demonstrate the therapeutic potential of Rev-erbα agonist against lung fibrosis.

Details

Title
Circadian clock molecule REV-ERBα regulates lung fibrotic progression through collagen stabilization
Author
Wang, Qixin 1 ; Sundar, Isaac Kirubakaran 2 ; Lucas, Joseph H. 1 ; Park, Jun-Gyu 3   VIAFID ORCID Logo  ; Nogales, Aitor 3 ; Martinez-Sobrido, Luis 3   VIAFID ORCID Logo  ; Rahman, Irfan 1   VIAFID ORCID Logo 

 University of Rochester Medical Center, Department of Environmental Medicine, Rochester, USA (GRID:grid.412750.5) (ISNI:0000 0004 1936 9166) 
 University of Kansas Medical Center, Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Kansas City, USA (GRID:grid.412016.0) (ISNI:0000 0001 2177 6375) 
 Texas Biomedical Research Institute, Disease Intervention and Prevention Program, San Antonio, USA (GRID:grid.250889.e) (ISNI:0000 0001 2215 0219) 
Pages
1295
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2785037988
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.